Type 1 diabetes mellitus is the result of the autoimmune response against pancreatic b-cell(s). At the time of clinical diagnosis near 70% of b-cell mass is been destroyed as a consequence of the auto-destruction that begins months or even years before the clinical diagnosis. Although marked reduction of chronic complications was seen after development and progression of insulin therapy over the years for type 1 diabetic population, associated risks of chronic end-organ damage and hypoglycemia still remain. Besides tight glucose […]